MRTNZ Investment Office · S&P 500 · The 360 Vantage
MO · NYSE
Altria Group, Inc.
Health Care · Medicinal Chemicals and Botanical Products
Reference price$74.82As of Jul 28, 2026
Street view
Analyst targets
Published sell-side aggregation—not an MRTNZ forecast.
Forward calendar
Current earnings expectations
Consensus may change until the company reports.
Dec 2026$5.70Street EPS consensus
Dec 2027$5.87Street EPS consensus
Dec 2028$6.06Street EPS consensus
Reported results
Annual financial snapshot
Fiscal period ended Dec 31, 2025.
MetricCurrentPrior
Revenue-3.1% YoY$23.28B$24.02B
Operating income$9.9B$11.24B
Net income$6.95B$11.26B
Operating cash flow$9.29B$8.75B
Capital expenditures($0.22B)($0.14B)
Current context
Related news
Company-linked articles surfaced by Nasdaq.
Evidence
Sources & method
Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →
Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.